Replacing Smad4 with various mutations in a smad−/− mammary cancer cell line showed that TGF-β signaling is greatly impaired by point mutations that naturally occur in cancer, and that in 2 of these cases signaling via a synthetic TGF-β reporter gene can be reactivated by simply inhibiting GSK3 activity. The gene discussed is SMAD4; the disease is breast cancer.